Biostatistics: Faculty Publications
Document Type
Article
Publication Date
11-15-2015
Publication Title
International Journal of Allergy Medications
ISSN
2572-3308
Abstract
This brief communication provides information to those developing monitoring plans for serious adverse events (SAE’s) following regulatory approval of a new drug. In addition, we (1) illustrate how many patients would need to be treated in order to have high confidence of seeing at least 1 pre-specified SAE, (2) show that absence of proof of a SAE is not proof of absence of that SAE, and (3) identify statistical methodology that could be used for formal statistical monitoring of SAE’s.
Recommended Citation
Peace, Karl E., Macaulay Okwuokenye.
2015.
"Monitoring for Adverse Events Post Marketing Approval of Drugs."
International Journal of Allergy Medications, 1 (2).
source: https://www.clinmedjournals.org/articles/ijam/international-journal-of-allergy-medications-ijam-1-010.pdf
https://digitalcommons.georgiasouthern.edu/biostat-facpubs/118
Copyright
This work is archived and distributed under the repository's Standard Copyright and Reuse License (opens in new tab). End users may copy, store, and distribute this work without restriction. For all other uses, permission must be obtained from the copyright owners or their authorized agents.
Comments
© 2015 Peace KE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.